Master of Clinical Integration in Traditional Chinese and Western Medicine, College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Ji-nan.
Department of Endocrinology and Metabology, First Affiliated Hospital of Shandong First Medical University.
Medicine (Baltimore). 2021 Jan 8;100(1):e23485. doi: 10.1097/MD.0000000000023485.
Coronavirus disease 2019 (COVID-19) is a respiratory infectious disease with a high fatality rate. Up to now, there are an estimated 26 million confirmed cases and 865,000 deaths around the world. But no effective way can control this disease. As the country that first discovered and treated the COVID-19, China has formed relatively mature prevention and treatment methods such as "3 prescriptions and 3 drugs." Xuan Fei Bai Du Fang, as a member of "3 prescriptions and 3 drugs," has very good clinical effects.
The PubMed, EMBASE, ClinicalTrials.gov, Cochrane Library, China National Knowledge Infrastructure, and Wanfang databases were searched for randomized controlled studies published to date. This study only screens clinical randomized controlled trials on QFBDF for COVID-19 to evaluate its efficacy and safety.Import all literatures that meet the requirements into Endnote X9 software. The information was finally cross-checked by 2 reviewers. Papers selected for review were assessed for risk of bias according to the criteria. Quality assessment on design of study, risk of bias, indirectness and imprecision were assessed using the GRADE framework. Where sufficient studies were available, publication bias was assessed visually using funnel plots. Relative risks for primary and secondary outcomes were calculated on an intent-to-treat basis and pooled using random effects meta-analysis. the continuous is expressed by mean difference or standard mean difference, eventually the data is synthesized using a fixed effect model or a random effect model depending on whether or not heterogeneity exists. The heterogeneity of studies will be evaluated by Q-test and I2 statistic with RevMan5.3.
The time from a positive diagnosis to a negative result of 2 consecutive nucleic acid tests (not on the same day), cure rate. The results of our research will be published in a peer-reviewed journal.
The purpose of this systematic review is to provide new evidence for the effectiveness and safety of Xuan Fei Bai Du Fang in the treatment of COVID-19.
CRD42020213950.
2019 年冠状病毒病（COVID-19）是一种具有高死亡率的呼吸道传染病。截至目前，全球估计有 2600 万确诊病例和 86.5 万人死亡。但目前还没有有效的方法可以控制这种疾病。作为首个发现和治疗 COVID-19 的国家，中国已经形成了较为成熟的防治方法，如“三药三方”。宣肺败毒方作为“三方三药”之一，具有很好的临床疗效。
检索PubMed、EMBASE、ClinicalTrials.gov、Cochrane Library、中国知网和万方数据库，筛选截至目前发表的关于宣肺败毒方治疗 COVID-19 的随机对照研究。本研究仅筛选临床随机对照试验，评估其疗效和安全性。将符合要求的文献全部导入 Endnote X9 软件。最后由 2 名评价者交叉核对。根据纳入和排除标准筛选文献，评价文献偏倚风险。采用 GRADE 框架评价研究设计、偏倚风险、间接性和不精确性的质量。当有足够的研究时，采用漏斗图进行发表偏倚评估。采用意向治疗原则，对主要和次要结局进行相对风险计算，并采用随机效应荟萃分析进行合并。连续变量采用均数差或标准化均数差表示，最终根据是否存在异质性采用固定效应模型或随机效应模型进行数据合成。采用 Q 检验和 I²统计量评价研究间的异质性，用 RevMan5.3 进行分析。
连续两次核酸检测（非同日）结果为阴性的时间、治愈率。研究结果将发表在同行评议期刊上。
本系统评价的目的是为宣肺败毒方治疗 COVID-19 的有效性和安全性提供新的证据。
PROSPERO 注册号：CRD42020213950。
